Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schneider, J. S.
Right arrow Articles by Rao, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schneider, J. S.
Right arrow Articles by Rao, J.

Neurology, Vol 45, Issue 6 1149-1154, Copyright © 1995 by American Academy of Neurology

ARTICLES

GM1 ganglioside treatment of Parkinson's disease: an open pilot study of safety and efficacy

JS Schneider, DP Roeltgen, DS Rothblat, J Chapas-Crilly, L Seraydarian and J Rao
Department of Neurology, Hahnemann University, Philadelphia, PA 19102, USA.

We performed an open-label study testing the effects of GM1 ganglioside on 10 Parkinson's disease (PD) patients. Patients received 1,000 mg of GM1 by IV infusion after the last of three baseline functional assessments. Patients then self-administered GM1 at a dose of 200 mg/d, by subcutaneous injection, for 18 weeks. Under these conditions, GM1 ganglioside proved to be safe and well tolerated. There were no serious adverse events and none of the patients developed elevated anti-GM1 antibody titers. Improvements on at least some functional measures were present in most patients, beginning after 4 to 8 weeks of GM1 treatment. When functional improvements occurred, they lasted for the duration of the study. These results suggest that GM1 ganglioside is well tolerated and may be a useful adjunct to the treatment of PD, and that a double-blind, placebo-controlled study is now warranted.


This article has been cited by other articles:


Home page
 J. Lipid Res.Home page
T. Nakagawa, A. Morotomi, M. Tani, N. Sueyoshi, H. Komori, and M. Ito
C18:3-GM1a induces apoptosis in Neuro2a cells: enzymatic remodeling of fatty acyl chains of glycosphingolipids
J. Lipid Res., June 1, 2005; 46(6): 1103 - 1112.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
B.M. Ravina, S.C. Fagan, R.G. Hart, C.A. Hovinga, D.D. Murphy, T.M. Dawson, and J.R. Marler
Neuroprotective agents for clinical trials in Parkinson's disease: A systematic assessment
Neurology, April 22, 2003; 60(8): 1234 - 1240.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. M. Crespo, A. R. Zurita, and J. L. Daniotti
Effect of Gangliosides on the Distribution of a Glycosylphosphatidylinositol-anchored Protein in Plasma Membrane from Chinese Hamster Ovary-K1 Cells
J. Biol. Chem., November 15, 2002; 277(47): 44731 - 44739.
[Abstract] [Full Text] [PDF]

Home page
 Innate ImmunityHome page
M. M. Prendergast and A. P. Moran
Review: Lipopolysaccharides in the development of the Guillain-Barre syndrome and Miller Fisher syndrome forms of acute inflammatory peripheral neuropathies
Innate Immunity, October 1, 2000; 6(5): 341 - 359.
[Abstract] [PDF]

Home page
 StrokeHome page
G. Grieco, M. d'Hollosy, A. T. Culliford, and S. Jonas
Evaluating Neuroprotective Agents for Clinical Anti-Ischemic Benefit Using Neurological and Neuropsychological Changes After Cardiac Surgery Under Cardiopulmonary Bypass : Methodological Strategies and Results of a Double-Blind, Placebo-Controlled Trial of GM1 Ganglioside
Stroke, May 1, 1996; 27(5): 858 - 874.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by AAN Enterprises, Inc.